OKYO Pharma Execs to Discuss NCP Pipeline at Piper Sandler Symposium
Event summary
- OKYO Pharma CEO Robert J. Dempsey and CMO Flavio Mantelli to participate in a fireside chat on July 9, 2026.
- Event moderated by Piper Sandler's Biren Amin at the Virtual Ophthalmology Symposium.
- Company recently completed Phase 2 trial of urcosimod for neuropathic corneal pain (NCP).
- Plans to initiate a 150-patient Phase 2b/3 study in H1 2026.
The big picture
OKYO's participation in Piper Sandler's symposium comes as it accelerates development of urcosimod, a potential first-in-class treatment for neuropathic corneal pain. The company is positioning itself in a niche but growing segment of ophthalmology focused on neuroinflammatory conditions. Success in Phase 2b/3 could significantly enhance its valuation and attractiveness to strategic partners.
What we're watching
- Clinical Momentum
- Whether OKYO can translate Phase 2 success into positive Phase 2b/3 results for urcosimod.
- Investor Sentiment
- How the market reacts to pipeline updates presented at the symposium.
- Competitive Positioning
- The pace at which OKYO advances its NCP program relative to peers in the ophthalmology space.